Inclusion Criteria:

- Histologically confirmed relapsed or refractory lymphoma

- Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) (phase I)

- Mature NHL, including the following cell types (phase II):

- Diffuse large B-cell lymphoma (DLBCL) with germinal center versus
non-germinal center phenotype as established by IHC

- Follicular lymphoma

- Lymphoma not otherwise specified (e.g., HL, T-NHL, marginal zone lymphoma,
lymphoplasmacytic lymphoma)

- No chronic lymphocytic leukemia or small lymphocytic lymphoma

- No bone marrow biopsies (with the exception of lymphoplasmacytic lymphoma) as sole
means of diagnosis

- Fine needle biopsies not allowed

- Must have received prior therapy

- Measurable disease, defined as any tumor mass > 1 cm

- Non-measurable disease alone, including the following, is not allowed:

- Bone lesions

- Ascites

- Pleural/pericardial effusion

- Lymphangitis cutis/pulmonis

- Bone marrow

- Waldenstrom's macroglobulinemia

- For Waldenstrom's macroglobulinemia measurable disease is defined as ≥
1 lesion with a single diameter of > 2 cm by CT or bone marrow
involvement > 10% malignant cells and quantitative monoclonal protein
(IgM, IgG, IgA) > 1,000 mg/dL

- No known CNS involvement

- No patients with relapsed or refractory DLBCL or HL who are eligible and willing to
undergo potentially curative stem cell transplantation

- ECOG performance status 0-2

- ANC ≥ 1,000/μL

- Platelet count ≥ 75,000/μL

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Gilbert
syndrome)

- AST/ALT ≤ 2.5 times ULN

- Creatinine clearance ≥ 60 mL/min

- Fasting serum cholesterol ≤ 350 mg/dL

- Fasting serum triglycerides ≤ 2.5 times ULN

- Not pregnant or nursing

- Two negative pregnancy tests (i.e., first test within 10-14 days before lenalidomide
and second test within 24 hours of starting lenalidomide)

- Fertile patients must agree to continue abstinence or begin using 2 methods of
effective contraception (one highly effective and one additional effective method) at
the same time for ≥ 28 days prior to start lenalidomide

- HIV-positive patients allowed provided the following criteria are met:

- No AIDS-defining illness

- CD4 count ≥ 400 cells/mm^3

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to temsirolimus or lenalidomide

- No currently active second malignancy other than nonmelanoma skin cancers

- Patients who have completed anticancer therapy for second malignancy and are
considered by their physicians to have < 30% risk of relapse allowed

- No deep venous thrombosis/pulmonary embolism (DVT/PE) within the past 3 months

- Patients with DVT/PE > 3 months ago must receive prophylactic aspirin or
low-molecular weight heparin

- No uncontrolled intercurrent illness including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness and/or social situations that would limit compliance with
study requirements

- No other concurrent anticancer commercial agents or therapies

- Any number of prior therapies allowed, including prior autologous transplantation

- More than 4 weeks since prior and no other concurrent chemotherapy or radiotherapy (6
weeks for nitrosoureas or mitomycin C) and recovered

- More than 7 days since prior and no concurrent antiretroviral therapy (including
HAART)

- No corticosteroids within the past 14 days except for maintenance of non-malignant
disease

- Prednisone or equivalent maintenance therapy dose < 10 mg/day

- No concurrent dexamethasone or other steroidal antiemetics

- No concurrent pegfilgrastim

- No other concurrent investigational agents